Introduction
Numerous large-scale clinical trials have demonstrated that statins (3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] reductase inhibitors) substantially reduce cardiovascular (CV) morbidity and mortality in both primary and secondary prevention of CV disease (CVD). A meta-analysis of individual data from 26 randomized trials of statins reported a 10% proportional reduction in all-cause mortality and a 20% proportional reduction in CV death/1.0 mmol/L (40 mg/dL) low-density lipoprotein-cholesterol (LDL-C) reduction. The risk of major coronary events was reduced by 23%, and the risk of stroke was reduced by 17%/mmol/L (40 mg/dL) LDL-C reduction. Thus, most international guidelines on CV prevention in clinical practice consider statin as the first-line medication of lipid-lowering treatment and recommend modulating the intensity of the preventive intervention according to the level of the total CV risk.

Atorvastatin, a member of the statins, was first synthesized in 1985. Since its approval by the US Food and Drug Administration in 1996, atorvastatin has become one of the best-selling drugs in pharmaceutical history. In China, atorvastatin is the most widely used lipid-lowering medication, accounting for about 40% of total statin use in secondary prevention of CVD. Besides, the efficacy and safety of atorvastatin have been testified by more than 200 randomized controlled trials (RCTs), with most sufficient clinical evidence among all statins. It is, therefore, important to evaluate the effect of atorvastatin in the Chinese population. In this paper, we conducted a review on the appraisal and patient considerations in the use of atorvastatin in the Chinese population.
Pharmacology, Mechanism of Action, and Pharmacokinetics

Atorvastatin calcium is a calcium salt of a chiral, penta-substituted pyrrole. Its molecular formula is C33H33CaFNO5, with a molecular weight of 582.6947. Like other statins, atorvastatin is a reversible and competitive inhibitor of HMG-CoA reductase. HMG-CoA reductase catalyzes the reduction of HMG-CoA to mevalonate, which is the rate-limiting step in cholesterol synthesis in the liver. Inhibition of the enzyme decreases de novo cholesterol synthesis.[11,12] Meanwhile, the partial depletion of cellular cholesterol by the action of the drugs leads to increasing expression of LDL receptors on hepatocytes. This increases LDL uptake by the hepatocytes, decreasing the amount of LDL-C in the blood. Inhibition of cholesterol synthesis in hepatocytes results in a decrease in very LDL-C production and an indirect reduction in LDL-C.[13] Like other statins, atorvastatin also reduces blood levels of triglycerides and slightly increases levels of high-density lipoprotein-cholesterol (HDL-C), although the mechanism is still not entirely clear.[14]

Atorvastatin undergoes rapid absorption and preferential uptake by the liver when taken orally. The absolute bioavailability of the parent drug is about 14%, but the systemic availability for HMG-CoA reductase activity is approximately 30%.[14] The time to reach peak plasma levels (Tmax) varies from 0.5 to 6 h.[13] Administration of atorvastatin with food results in a prolonged Tmax, as well as in a reduction in maximum concentration (Cmax) and area under the curve (AUC). However, changes in the rate of atorvastatin absorption are not expected to have a clinically significant effect, as subsequent multiple-dose clinical studies have shown that dose, but not plasma atorvastatin concentration profiles, correlates with lipid-lowering effects.[15] Although the rate and the extent of equivalent absorption of atorvastatin were lower during evening than morning administration, the time of administration did not affect the plasma LDL-C-lowering efficacy of atorvastatin.[17] Atorvastatin is highly protein bound (≥98%). The major metabolic pathway of atorvastatin is through cytochrome P450 3A4 hydroxylation to form active orthohydroxylated and parahydroxylated metabolites, as well as various beta-oxidation metabolites. The orthohydroxylated and parahydroxylated metabolites are responsible for 70% of systemic HMG-CoA reductase activity. As a substrate for the CYP3A4, atorvastatin is expected to have drug-drug interaction with concurrent administration of potential inhibitors or inducers of this system.[18,19] Moreover, several genetic studies have found that CYP gene polymorphisms are associated with the metabolism of atorvastatin in the Chinese population and thus affect the lipid-lowering effect of atorvastatin [Table 1].[20-23] Atorvastatin is primarily eliminated via hepatic biliary excretion without entero-hepatic recirculation and <2% recovered in the urine. Atorvastatin has an approximate elimination half-life of 14 h. However, the HMG-CoA reductase inhibitory activity appears to have a half-life of 20–30 h, which is thought to be due to the active metabolites.[14]

Whether there is a differing pattern of systemic exposure to atorvastatin among Chinese versus Caucasian subjects was studied by Gandelman et al. by comparing data obtained from 310 Asians (31% Chinese) and 572 Caucasians in 22 pharmacokinetic studies. They found that the equivalent dose/bodyweight normalized AUC (Asian = 157.5, Caucasian = 156.4 [ng·h·ml⁻¹]/[mg/kg]) and Cmax (Asian = 26.2, Caucasian = 30.3 [ng/ml]/[mg/kg]) for atorvastatin were similar in both ethnic groups. They concluded that dosing considerations in atorvastatin are similar for Asian compared with Caucasian subjects.[24]

Efficacy of atorvastatin in lipid-lowering

A recent meta-analysis of 254 trials evaluating the dose-related efficacy of atorvastatin in 33,505 participants concluded that the blood total cholesterol, LDL-C, and triglyceride-lowering effect of atorvastatin were dependent on dose. Log dose-response data were linear over the commonly prescribed dose range. Atorvastatin of 10–80 mg/day resulted in 36%–53% decreases of LDL-C. However, there was no significant dose-related effect of atorvastatin on HDL-C.[10] To address the question of whether the lipid responses to atorvastatin may differ between Chinese and Caucasians, Hu et al. used the data from the direct statin comparison of LDL-C Values: An evaluation of rosuvastatin therapy (DISCOVERY) program. They found that there was a similar percentage reduction

---

**Table 1: Gene polymorphisms associated with the metabolism of atorvastatin in Chinese population**

| Authors, year | Study population | n | Target gene | Atorvastatin | Lipid lowering results |
|---------------|-----------------|---|-------------|--------------|------------------------|
| Gao et al., 2008 | Hyperlipidemic patients | 217 | CYP3A4*1G | 20 mg/day × 4 weeks | TC*↓: 16.8% for the *1/*1 carriers, 17.8% for the *1/*G carriers, and 20.9% for the *G/*G carriers |
| Li et al., 2011 | Hyperlipidemic patients | 177 | CYP3AP1*3 | 20 mg/day × 4 weeks | LDL-C↓: 28.62% for the CYP3AP1*3/*3 carriers, and 25.53% for the CYP3AP1*1 carriers |
| Wei et al., 2011 | Hyperlipidemic patients | 185 | CYP7A1 A-204C ABCG8 C1199A | 20 mg/day × 4 weeks | The CYP7A1-204A and ABCG8 1199A alleles appear to interact to affect triglyceride lowering response |
| Jiang et al., 2012 | Hyperlipidemic patients | 170 | CYP7A1 | 20 mg/day × 60 days | LDL-C↓: 27.89% for the GG/GA carriers and 35.26% for the AA carriers |

*Total cholesterol; †LDL-C: Low-density lipoprotein cholesterol.*
in LDL-C in response to atorvastatin 10 mg/day in Hong Kong Han Chinese patients compared with those in patients from a mixture of other Asian or Western countries in the DISCOVERY program.[25]

Primary prevention of cardiovascular disease

The results of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) showed that hypertensive patients with mildly elevated cholesterol levels who took atorvastatin 10 mg daily had 36% fewer nonfatal myocardial infarction (MI) and fatal coronary artery disease than patients treated with placebo.[26] However, ASCOT only enrolled patients in the United Kingdom, Ireland, and Nordic countries. In a surrogate study from China, 151 patients with mild hypertension were randomly divided into three groups: Atorvastatin 10 mg group, atorvastatin 20 mg group and the control group. After 3 months, LDL-C was decreased by 30% in the atorvastatin 10 mg group and 40.48% in the 20 mg group, consistent with the lipid-lowering effect in ASCOT. Carotid intima media thickness was decreased, and endothelial function was improved in both atorvastatin groups.[27] This result was further confirmed by Ge et al. A total of 126 hypertensive patients with hypercholesterolemia were randomized into amiodipine 10 mg/day group and amiodipine 10 mg/day plus atorvastatin 20 mg/day group. After 4 months of treatment with atorvastatin, serum total cholesterol, LDL-C, triglyceride, high sensitive-C reactive protein, and uric acid decreased significantly in the amiodipine plus atorvastatin group, while HDL-C increased (P < 0.05). Meanwhile, compared with that before treatment, left ventricular mass index in both groups decreased (P < 0.05), to a significantly lower degree in the amiodipine plus atorvastatin group than in the amiodipine group (P < 0.05).[28]

Type 2 diabetes mellitus (T2DM) is an important risk factor for developing CVD, and it has an atherogenic lipid profile consisting of elevated triglyceride and low HDL-C, which results in high non-HDL-C levels. In the Collaborative Atorvastatin Diabetes Study, 2,838 patients with diabetes aged 40–75 years in 132 centers in the United Kingdom and Ireland were randomized to placebo or atorvastatin 10 mg daily, and atorvastatin 10 mg daily is efficacious in reducing the risk of first CVD events by 37% (rate reduction 37%, 95% confidence interval [CI] -52 to -17; P = 0.001).[29] The ASCOT substudy further confirmed that atorvastatin 10 mg daily significantly reduced the risk of major CV events or procedures (hazard ratio [HR]: 0.77, 95%CI: 0.61–0.98; P = 0.036) among diabetic patients with well-controlled hypertension and without a history of coronary artery disease or markedly elevated cholesterol concentrations. The proportional reduction in risk was similar to that among participants who did not have diagnosed diabetes.[30] However, the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in noninsulin-dependent diabetes mellitus, another RCT to access the efficacy of atorvastatin in subjects with T2DM failed to find a significant reduction in the primary composite end point comparing 10 mg of atorvastatin with placebo in both primary and secondary prevention (HR: 0.90, 95%CI: 0.73–1.12; P = 0.34), which may relate to the overall study design, the types of subjects recruited, sample size, and the protocol changes required because of changing treatment guidelines.[31] None of these three studies included Chinese population. Recently, Su et al. reported data of 151 diabetic patients treated with simvastatin 40 mg/day or atorvastatin 10 mg/day and found that both statins treatment significantly decreased plasma lipids in all patients with T2DM without a significant difference between the two groups. However, the effects of atorvastatin in increasing nitric oxide concentration and glutathione peroxidase, and superoxide dismutase activity, and in decreasing malondialdehyde level were significantly greater than those of simvastatin in patients with T2DM compared, suggesting that atorvastatin reduced oxidative stress more effectively than simvastatin did in patients with T2DM.[32] Liu et al. proved that both atorvastatin 10 mg/day and pravastatin 2 mg/day were effective in reducing the LDL-C level in Chinese diabetic patients, as well as in improving insulin resistance and endothelial function.[33] Another study also found that atorvastatin 80 mg/day has a similar effect on endothelial, platelet, and angiogenic indices in both South Asians and European with diabetes.[34]

A meta-analysis of 20 RCTs investigating different statins has demonstrated that using statins in a high-risk population for primary prevention is associated with a significant reduction in all-cause death, CV death, and major CV events.[35] This conclusion was confirmed by a recent network meta-analysis, and there is no significant difference between atorvastatin and other statins in primary prevention.[36] However, whether primary prevention is beneficial in individuals at low or modest risk is still uncertain.

Secondary prevention of cardiovascular disease

The Incremental Decrease in End Points through Aggressive Lipid Lowering trial found that intensive lowering of LDL-C with atorvastatin 80 mg/day did not result in a significant reduction in the primary outcome of major coronary events (HR: 0.89, 95%CI: 0.78–1.01; P = 0.07), but did reduce the risk of major CV events (HR: 0.87, 95%CI: 0.77–0.98; P = 0.02) and nonfatal acute MI (HR: 0.83, 95%CI: 0.71–0.98; P = 0.02) in patients with previous MI, when compared with usual dose simvastatin (20 mg/day).[37] Meanwhile in the treating to new targets study, 10,001 patients with stable coronary artery disease were randomized to receive atorvastatin 10 or 80 mg/day to achieve LDL-C goals of <100 and 70 mg/dL, respectively. Atorvastatin 80 mg/day reduced the risk of CV events to a significantly greater extent than atorvastatin 10 mg/day (HR: 0.78, 95%CI: 0.69–0.89; P < 0.001). However, the risk of overall mortality was similar in atorvastatin 80 mg/day recipients, compared with atorvastatin 10 mg/day recipients.[38] In China, 228 patients with stable atherosclerotic plaques who had undergone coronary arteriography and intravascular ultrasound were randomly assigned to receive placebo or atorvastatin at a single daily dose of 10 mg, 20 mg, 40 mg, or 80 mg. At 6 months
of follow-up, the LDL-C levels in the atorvastatin groups were below those at their respective baselines (All P < 0.01). The percentages of plaque necrosis following treatment in the placebo and atorvastatin 10 mg groups rose above baseline levels (15.51 ± 12.56 vs. 7.69 ± 1.31%, P < 0.01; 13.54 ± 11.76 vs. 7.83 ± 1.43%, P < 0.01, respectively) while the atorvastatin 20, 40, and 80 mg groups remained stable. Plaque volumes in the atorvastatin 40 and 80 mg groups decreased significantly compared with baseline plaque volumes (30.69 ± 8.12 vs. 37.09 ± 12.01 mm³, P = 0.019; 24.99 ± 1.01 vs. 36.47 ± 14.68 mm³, P < 0.01, respectively).^{39}

Several large RCTs have been conducted to assess the efficacy of high-dose atorvastatin in patients with acute coronary syndrome (ACS). In the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering study, 3,086 patients with unstable angina pectoris or non-Q-wave MI were randomized within a mean of 63 h after hospitalization to receive atorvastatin 80 mg/day or placebo for 16 weeks in addition to usual therapy. Atorvastatin therapy reduced the incidence of death, nonfatal acute MI, cardiac arrest with resuscitation, or recurrent symptomatic myocardial ischemia with objective evidence and requiring emergency rehospitalization compared with placebo (relative risk 0.84, 95%CI: 0.70–1.00; P = 0.048).^{38} The Pravastatin or Atorvastatin Evaluation and Infection Therapy (IMPROVE IT-TIMI22) study enrolled 4162 patients who had been hospitalized for an ACS within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). After a 2 year follow-up, intensive lipid-lowering statin regimen provides greater protection against death or major adverse cardiac events (MACEs) (MI, documented unstable angina requiring rehospitalization, revascularization, and stroke) than a standard regimen (HR: 0.84, 95%CI: 0.74–0.95, P = 0.005).^{40}

The efficacy of intensive lipid-lowering with high-dose atorvastatin in ACS patients has also been investigated in the Chinese population. In the study by Dong et al., 92 patients with ACS post successful percutaneous coronary intervention (PCI) were randomly divided into atorvastatin 10 mg/day and atorvastatin 40 mg/day on top of the standard medical therapy for 24 weeks. Total cholesterol and LDL-C in atorvastatin 40 mg/day group were significantly lower than in 10 mg/day group, as were the high-sensitive C reactive protein and Matrix metalloproteinases-9. Due to the small sample size, there is no difference in the incidence of MACEs between the two groups.^{41} Another surrogate study by Zhao et al. further access the efficacy of high-dose atorvastatin in elderly Chinese patient with unstable angina and 166 patients with unstable angina who were ≥60 years of age, randomly assigned to receive atorvastatin 80 or 20 mg/day. Atorvastatin 80 mg/day was associated with a significant reduction in LDL-C, inflammatory factors, and improvement of endothelial function.^{42} Yu et al. found that even a short-term pretreatment with a high dose of atorvastatin (80 mg 12 h before PCI, with a further 40 mg preprocedure dose) could reduce the 30 day incidence of MACEs in Chinese patient with non-ST elevation ACS (2.4% vs. 22.5%, P = 0.016), which mainly attributed to the reduction in the incidence of MI (2.4% vs. 20.0%, P = 0.031).^{43} However, these studies have several limitations, including small sample size, low study quality, short study duration, and the use of surrogate endpoints instead of clinical endpoints.

Considering these limitations, several large RCTs have been initiated to evaluate the efficacy and safety of atorvastatin in Chinese patients with coronary artery disease. The China intensive lipid lowering with statins in ACS (CHILLAS) study is an open-label multicenter study in China to evaluate whether intensive treatment with statins for 2–5 years results in a greater reduction of CV events in patients with ACS compared with the standard statin therapy. A total of 1600 patients will be randomly assigned to receive intensive statin therapy (atorvastatin, 20 or 40 mg/day, or equivalent dose of other statins) or standard statin therapy (atorvastatin, 10 mg/day, or equivalent dose of other statins). The primary outcome of the study is the time to occurrence of cardiac death, nonfatal MI, revascularization with either PCI or coronary artery bypass surgery, documented unstable angina or severe heart failure requiring emergency hospitalization, and stroke. The CHILLAS study will be the first multicenter study in a Chinese population using a patient-level analysis to compare the effects and safety of intensive statin therapy with that of standard-dose statin therapy.^{44} An Intensive statin therapy for Chinese patients with coronary artery disease undergoing PCI (ISCAP) study is also designed to evaluate the safety and efficacy of intensive statin therapy and the long-term outcome of patients in the Chinese population. Approximately, 1,100 patients with stable angina or non-ST elevation ACS undergoing selective PCI will be enrolled and randomized either to the intensive group (atorvastatin 80 mg/ day × 2 days before and 40 mg/day × 30 days after PCI) or to the control group (usual care). The primary outcome is 30 day MACEs, and secondary outcomes are 6 months MACEs and change in biomarkers. The result of the ISCAP study will provide important evidence on the efficacy and safety of peri-procedural serial intensive statin treatment in Chinese patients with coronary artery disease undergoing selective PCI.^{45}
Compared with an increased risk of development of diabetes, recently statin therapy was found to be associated with other statins. 

Chinese population was similar to that observed with placebo significant adverse events observed with atorvastatin in and low-dose atorvastatin. Thus, the overall incidence of adherence to medications, did not differ between high-dose ULN, as well as the risk of musculoskeletal toxicity and of elevated ALT. However, the risk of elevated ALT > 3 atorvastatin (40–80 mg/day) has a significantly higher risk with low-dose atorvastatin (10–20 mg/day), high-dose and placebo (0.8% [n = 14]), and other statin (2.0% [n = 105]) groups, and was not related to the atorvastatin dose. No cases of rhabdomyolysis or myopathy were reported. The overall incidence of treatment-associated adverse events observed with atorvastatin did not increase in the 10–80 mg dose range and was similar to that observed with placebo and in patients treated with other statins. Specific analysis of musculoskeletal and hepatic adverse events showed that these infrequently occurred and rarely resulted in treatment discontinuation. 

An updated pooled analysis of 49 clinical trials comparing the safety of atorvastatin 10 mg/day, atorvastatin 80 mg/day, and placebo further confirm that the incidence of treatment-associated adverse events for atorvastatin 80 mg/day was similar to that of atorvastatin 10 mg/day and placebo, as well as the incidence withdrawals due to treatment-related adverse events.

To fully evaluate the safety and adherence of atorvastatin in the Chinese population, we conducted a systemic search of the literature in PubMed using the keywords “atorvastatin” (Supplementary concept) or “atorvastatin” (All field) and (“China” [AD] or “China” [all field] or “Chinese” [All field]) to identify all the RCTs comparing atorvastatin with control/placebo or other statins and reporting the incidence of side-effect. Thirteen RCTs with 4,145 patients were finally included [Table 2]. The incidence of hepatic and musculoskeletal toxicity and the adherence of medication were pooled using the Mantel-Haenszel Method with random effect model (STATA 11.0; STATA Corp., TX, USA). No case of rhabdomyolysis or CK > 10 ULN was reported. The risk of hepatic and musculoskeletal toxicity did not differ between atorvastatin and control/placebo groups, as well as the adherence of medication. Besides, atorvastatin has a similar risk of hepatic and musculoskeletal toxicity and adherence of medication with other statins. When compared with low-dose atorvastatin (10–20 mg/day), high-dose atorvastatin (40–80 mg/day) has a significantly higher risk of elevated ALT. However, the risk of elevated ALT > 3 ULN, as well as the risk of musculoskeletal toxicity and adherence to medications, did not differ between high-dose and low-dose atorvastatin. Thus, the overall incidence of significant adverse events observed with atorvastatin in Chinese population was similar to that observed with placebo or other statins [Figure 1].

Recently, statin therapy was found to be associated with an increased risk of development of diabetes, and it is believed that different types and doses of statins show different potential to increase the incidence of diabetes. Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new-onset diabetes. However, a retrospective cohort study of 15,637 Chinese hypertensive and dyslipidemic patients demonstrated that patients who take atorvastatin or rosuvastatin are at lower risk of new-onset diabetes, while lovastatin and simvastatin were associated with a significant increase in the risk of new-onset diabetes. Compared with lower-dose atorvastatin, atorvastatin 80 mg/day did not increase the incidence of new-onset diabetes in patients with 0 to 1 risk factors but did, by 24%, among patients with two to four risk factors for new-onset diabetes. Of note, the risk of new-onset diabetes is low both in absolute terms and when compared with a reduction in coronary events.

Limitations
First, only few studies were designed to compare the difference in use of atorvastatin directly between Chinese and western population. Thus, the major conclusions of the review were based on the indirect comparison. Second, high-quality evidence on atorvastatin, as well as the other statins, remained unavailable in Chinese population.

Conclusion
Although the benefit of atorvastatin in primary and secondary prevention has been verified by abundant of international multiple-center RCTs, none of them included the Chinese population, and the evidence of atorvastatin in the Chinese population is still insufficient. However, based on the current available evidence, there is no significant difference between the Chinese and non-Chinese populations in terms of pharmacology and clinical efficacy. Moreover, atorvastatin is well-tolerated and well-accepted by Chinese patients. Thus, atorvastatin still should be considered as one of the
Table 2: Safety outcomes and patients adherence of atorvastatin in randomized controlled trials with Chinese population

| Author, year | Study population | n  | Duration | Primary outcomes | Intervention | Elevated ALT | ALT > 3 ULN** | Myalgia | CK*** > 10 ULN | Rhabdomyolysis | Adherence (%) |
|--------------|------------------|----|----------|-----------------|--------------|--------------|-------------|---------|----------------|----------------|---------------|
| Dong et al. 2006 | ACS*             | 92 | 24 weeks | hs-CRP; MMP-9#  | Atorvastatin 10 mg/day | 9/46 | 2/46 | NA ### | NA | NA | 43/46 (93.5) |
| Lam et al. 2006 | Diabetes         | 29 | 12 weeks | Endothelin-1    | Atorvastatin 40 mg/day | 19/46 | 3/46 | NA | NA | NA | 42/46 (91.3) |
| Gao et al. 2007 | Hyperlipidemia  | 290| 20 weeks | Lipid profile   | Atorvastatin 10 mg/day | 1/99 | 0/99 | NA | 0/99 | 0/99 | 93/99 (93.9) |
| Wu et al. 2007  | Hypertension     | 151| 12 months | CIMT**          | Atorvastatin 10 mg/day | NA | NA | 0/61 | NA | 0/61 | 61/61 (100) |
| Yu et al. 2007  | CAD†             | 112| 26 weeks | CIMT            | Atorvastatin 80 mg/day | 2/57 | NA | NA | NA | NA | 54/57 (94.7) |
| Zhu et al. 2007 | Hyperlipidemia  | 1482| 12 weeks | Lipid profile   | Rosuvastatin 10 mg/day | NA | NA | 8/995 | 0/995 | 942/995 (94.7) |
| Han et al. 2009 | CAD post PCI‡    | 1275| 12 months | MACE††          | Atorvastatin 20 mg/day | 21/638 | NA | 8/86 | NA | 617/638 (96.7) |
| Zhao et al. 2009| UA, >60 years    | 166| 8 weeks | Inflammatory    | Provastatin 20 mg/day | 16/637 | NA | 5/56 | NA | 621/638 (97.3) |
| Sun et al. 2010 | Non-ST elevation ACS | 80| 30 days | MACE           | Atorvastatin 40 mg/day | 0/20 | 0/20 | 0/20 | 0/20 | 20/20 (100) |
| Liu et al. 2011 | Stable CAD       | 36 | 4 weeks | Endothelial function | Atorvastatin (LD) 80 mg; (MD) 40 mg/day | 0/20 | 0/20 | 0/20 | 0/20 | 20/20 (100) |
| Yu et al. 2011  | Non ST elevation ACS | 81| 30 days | MACE           | Atorvastatin (LD) 80 mg; (MD) 40 mg/day | 1/20 | 0/20 | 0/20 | 0/20 | 20/20 (100) |
| Liu et al. 2013 | High risk of CAD | 251| 12 weeks | Lipid profile   | Atorvastatin 10 mg/day | 6/40 | 0/40 | 0/40 | 0/40 | 40/40 (100) |
| Zhang et al. 2013| UA§              | 100| 9 months | Progression of atherosclerotic plaques | Atorvastatin 80 mg/day | 13/50 | 0/50 | 0/50 | 0/50 | 32/50 (64) |
|                |                  |    |          |                 | Atorvastatin 20 mg/day | 4/50 | 0/50 | 0/50 | 0/50 | 30/50 (60) |

*Acute coronary syndrome; †Coronary artery disease; ‡Percutaneous coronary intervention; §Unstable angina; ||High sensitive C reactive protein; #Matrix metalloproteinases; **Carotid intima thickness; ††Major adverse cardiac event; †‡Loading dose; †§Maintain dose; |||Alanine aminotransferase; ###Upper limit of normal; ***Creatine phosphokinase; ###Not available.
first-line medication in Chinese patients with lipid disorders. However, high-quality evidence is needed to support the use of atorvastatin in high-risk Chinese population.

**References**

1. Brugts JJ, Yetgin T, Hocks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.

2. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: A network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769-81.

3. Cholesterol Treatment Trials’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.

4. European Association for Cardiovascular Prevention and Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/ewing guidelines for the management of dyslipidemias: The task force for the management of dyslipidemias of the European society of cardiology (esc) and the European atherosclerosis society (eas). Eur Heart J 2011;32:1769-818.

5. China Initiative on Clinical Control of Dyslipidemia Expert Group. Expert recommendations on attaining the goal for treatment of hypercholesterolemia in clinical practice. Zhonghua Xin Xue Guan Bing Za Zhi 2010;38:294-8.

6. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report. Circulation 2002;106:3143-421.

7. Li J, Chen YP, Li X, Armitage J, Feng F, Liu JM, et al. Use of secondary preventive medications in patients with atherosclerotic disease in urban China: A cross-sectional study of 16, 860 patients. Chin Med J (Engl) 2012;125:4361-7.

8. Gao F, Zhou YJ, Hu da Y, Zhao YY, Liu YY, Wang Zh et al. Contemporary management and attainment of cholesterol targets for patients with dyslipidemia in China. PLoS One 2013;8:e47681.

9. Adams SP, Tsang M, Wright JM. Lipid lowering efficacy of atorvastatin. Cochrane Database Syst Rev 2012;12:CD008226.

10. Kearney AS, Crawford LF, Mehta SC, Radebaugh GW. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. J Pharmacol Exp Ther 1993;10:1461-5.

11. Hoeg JM, Brewer HB Jr. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA 1987;258:3532-6.

12. Tobert JA. New developments in lipid-lowering therapy: The role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation 1987;76:534-8.

13. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24-33.

14. Chong PH, Seeger JD. Atorvastatin calcium: An addition to HMG-CoA reductase inhibitors. Pharmacotherapy 1997;17:1157-77.

15. Posvar EL, Radulovic LL, Cilla DD Jr, Whitfield LR, Sedman AJ. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol 1996;36:726-31.

16. Radulovic LL, Cilla DD, Posvar EL, Sedman AJ, Whitfield LR. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 1995;35:990-4.

17. Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normcholesterolemic subjects in the morning and evening. J Clin Pharmacol 1996;36:604-9.

18. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P. Intraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000;68:391-400.

19. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: Results of AIDS clinical trials group 5108 study. J Acquir Immune Defic Syndr 2005;39:307-307.

20. Gao Y, Zhang LR, Fu Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol 2008;64:877-82.

21. Li YP, Zhang LR, Jia M, Hu XJ. CYP3A5*1 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women. J Clin Pharmacol 2011;51:181-8.

22. Wei KK, Zhang LR, Zhang Y, Hu XJ. Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin. J Clin Pharm Ther 2011;36:725-33.

23. Jiang XY, Zhang Q, Chen P, Li SY, Zhang NN, Chen XD, et al. CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin. J Clin Pharm Ther 2012;37:719-23.

24. Gandolm K, Fung GL, Messig M, Laskey R. Systemic exposure to atorvastatin between Asian and caucasian subjects: A combined analysis of 22 studies. Am J Ther 2012;19:164-73.

25. Hu M, Lui SS, Ko GT, Tomlinson B. Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and caucasians? Comparison of the discovery-Hong Kong study with other discovery studies. Int J Cardiol 2013;168:3071-3.

26. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beesers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo‑Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT‑LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-58.

27. Wu J, Wu G, Wang MP, Liu DL, Hu ZJ, Xu GY. Effect of atorvastatin on carotid intima-medial thickness of primary hypertension patients of Han nationality in China. Zhonghua Yi Xue Za Zhi 2007;87:2215-7.

28. Ge CJ, Lu SZ, Chen YD, Wu XF, Hu SJ, Ji Y. Synergistic effect of ambloplide and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels 2008;23:91-5.

29. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDs): Multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.

30. Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, et al. Reduction in cardiovascular events with atorvastatin in 25,321 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial – Lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005;28:1151-7.

31. Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29:1478-85.

32. Hu Y, Xu Y, Sun YM, Li J, Liu XM, Li YB, et al. Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol 2010;55:21-5.

33. Liu PY, Lin LY, Lin HJ, Hsie CH, Hung YR, Yeh HL, et al. Pitavastatin and atorvastatin double-blind randomized comparative study among higH-risk patients, including those with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). PLoS One 2013;8:e76298.

34. Jaumdally RJ, Lip GY, Varney C, Blann AD. Impact of high-dose atorvastatin on endothelial, platelet, and angiogenic indices: Effect of ethnicity, cardiovascular disease, and diabetes. Angiology 2011;62:571-8.

35. Naci H, Brugs JF, Flureece R, Tsoi B, Toor H, Ades AE. Comparative benefits of statins in the primary and secondary prevention of major
coronary events and all-cause mortality: A network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol 2013;20:641-57.

36. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA 2005;294:2437-45.

37. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.

38. Guo S, Wang R, Yang Z, Li K, Wang Q. Effects of atorvastatin on serum lipids, serum inflammation and plaque morphology in patients with stable atherosclerotic plaques. Exp Ther Med 2012;4:1069-74.

39. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary events: The MIRACL study: A randomized controlled trial. JAMA 2001;285:1711-8.

40. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.

41. Dong SH, Wen JM, Luo LJ, Chen KQ, Liang XJ, Li YF, et al. The effects of 40 mg atorvastatin on serum lipids, inflammatory markers and clinical events in ACS patients post PCI. Zhonghua Xin Xue Guan Bing Za Zhi 2006;34:353-6.

42. Zhao Z, Geng J, Ge ZM, Wang W, Zhang Y, Kang WQ. Efficacy and safety of atorvastatin during early hospitalization in elderly patients with unstable angina. Clin Exp Pharmacol Physiol 2009;36:554-8.

43. Yu XL, Zhang HJ, Ren SD, Geng J, Wu TT, Chen WQ, et al. Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury. Coron Artery Dis 2011;22:87-91.

44. Zhao SP, Peng DQ, Yu BL, Huo Y, CHILLAS investigators. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: The CHILLAS study. Am Heart J 2009;158:119-25.

45. Liu P, Jiang J, Li J, Hong T, Zhang Y, Kang WQ. Efficacy and safety of atorvastatin derived from analysis of 49 completed trials in 9,416 patients. Am J Cardiol 2003;92:670-6.

46. Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 2003;92:670-6.

47. Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006;97:61-7.

48. Lam HC, Chu CH, Wei MC, Keng HM, Lu CC, Sun CC, et al. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia. Exp Biol Med (Maywood) 2006;231:1010-5.

49. Gao RL. The efficacy and safety of rosuvastatin on treating patients with hypercholesterolemia in Chinese: A randomized, double-blind, multi-center clinical trial. Zhonghua Xin Xue Guan Bing Za Zhi 2007;35:207-11.

50. Yu CM, Zhang Q, Lam L, Lin H, Kong SL, Chan W, et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart 2007;93:933-9.

51. Zhu JR, Tomlinson B, Ro YM, Sim KH, Lee YT, Sriratanasathavorn C. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Curr Med Res Opin 2007;23:3055-68.

52. Han YL, Zhang ZL, Li Y, Wang SL, Jing QM, Wang ZL, et al. Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting: A randomized controlled trial. Zhonghua Yi Xue Za Zhi 2009;89:2240-4.

53. Sun Y, Qi G, Gao Y, Zhang H, Pang X, Zhao W, et al. Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes. Can J Cardiol 2010;26:481-5.

54. Liu B, Cao HM, Li GY, Liu M, Feng J, Li J, et al. Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endothelial function in patients with atherosclerosis. J Int Med Res 2011;39:2314-22.

55. Zhang X, Wang H, Liu S, Gong P, Lin J, Lu J, et al. Intensive-dose atorvastatin regimen halts progression of atherosclerotic plaques in new-onset unstable angina with borderline vulnerable plaque lesions. J Cardiovasc Pharmacol Ther 2013;18:119-25.

56. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.

57. Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013;111:1123-30.

58. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: Population based study. BMJ 2013;346:f2610.

59. Ma T, Chang MH, Tien L, Liou YS, Jang GJ, et al. High-dose atorvastatin vs usual-dose simvastatin for acute coronary syndromes. Can J Cardiol 2010;26:481-5.

60. Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: Effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013;61:148-52.

Received: 25-06-2014 Edited by: Jian Gao
How to cite this article: Ye YC, Zhao XL, Zhang SY. Use of Atorvastatin in Lipid Disorders and Cardiovascular Disease in Chinese Patients. Chin Med J 2015;128:259-66.

Source of Support: Nil. Conflict of Interest: None declared.